Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Palvella Therapeutics, Inc.

NASDAQ: PVLA · Life Sciences · 7 alerts · CIK 1583648

Share price
$144.60Close, Nov 16
Market cap
$2.11B
Shares outstanding
14.62MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Palvella Therapeutics, Inc. filings on SEC EDGAR ↗

7:30 AM ET 8-K
Business Update

Palvella Therapeutics Business Update

Palvella Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for QTORIN™ 3.9% rapamycin anhydrous gel and granted it Priority Review. The application seeks approval for the treatment of microcystic lymphatic malformations, with a PDUFA target action date set for February 28, 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.